Indication intelligence, analysis and sector perception

UniQure (QURE) Licenses cell line and technology from Protein Sciences

June 29, 2016 9:18am

For production of its human gene therapy products based on rAAV vectors

Protein Sciences says it exclusively licensed its expresSF+ cell line and associated technology to QURE for production of human gene therapy products.

The Bottom Line: The companies, which have had a relationship that spans nearly a decade, will expand their agreement to include uniQure's broad pipeline of investigational gene therapies in development. Protein Sciences will get undisclosed upfront payment and is eligible for one-time milestone payment.

QURE closed at $7.37. 6/17 QURE was trading at $9.35 which has seen a steady decline since 6/1 when QURE was trading at $13.41. May’s trading range was $11.71 to $13.55. I’d be a buyer holding a “joker” card - BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.